MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib.
Young, Adelaide I J; Law, Andrew M K; Castillo, Lesley; Chong, Sabrina; Cullen, Hayley D; Koehler, Martin; Herzog, Sebastian; Brummer, Tilman; Lee, Erinna F; Fairlie, Walter D; Lucas, Morghan C; Herrmann, David; Allam, Amr; Timpson, Paul; Watkins, D Neil; Millar, Ewan K A; O'Toole, Sandra A; Gallego-Ortega, David; Ormandy, Christopher J; Oakes, Samantha R.
Breast Cancer Res
; 18(1): 125, 2016 12 08.
Artigo em Inglês | MEDLINE | ID: mdl-27931239
The life history of 21 breast cancers.
Breast surgery for metastatic breast cancer.
Aldehydes Pose a Threat to BRCA2 Mutation Carriers.
Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution.
A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds.
Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance.
Localization techniques for guided surgical excision of non-palpable breast lesions.
Revisiting the role of MCL1 in tumorigenesis of solid cancer: gene expression correlates with antiproliferative phenotype in breast cancer cells and its functional regulatory variants are associated with reduced cancer susceptibility.
Endogenous tRNA-Derived Fragments Suppress Breast Cancer Progression via YBX1 Displacement.
[Effect of death decoy receptor 3 on prognosis of breast cancer and function of breast cancer cells <i>in vitro</i>].